Aims and Objectives (download flyer here):
The objective of OptiCryst's research platform is the development, implementation and exploitation of new technologies to overcome the bottleneck of protein crystal optimisation. This will be achieved by integrating complementary techniques in a concerted effort by 7 SMEs and 4 academic groups. The OptiCryst consortium will develop research outputs aimed at crystallising proteins of high therapeutic value, with the goal of using this information for novel drug development.

Participants:
Aston University; Imperial College London; Douglas Instruments Ltd; Key Drug Prototyping BV;
Molecular Dimensions Ltd; Triana Science & Technology; University of Luebeck; Farfield Scientific Ltd.;
Consejo Superior de Investigaciones Cientificas; PLS-Design GmbH; Gothia Yeast Solutions AB

EC contract no. LSH-2005-037793 / EC contribution: 2.268.531,00 Euro
Project duration: 36 months / Start: Dec 01, 2006 / 7 small-to-medium enterprises & 4 academic institutions.